Evidence map›Paper›PMID 41846597›Full record

Trial reportOpen forum infectious diseases2026

A Double-blind Randomized Trial of Oral Chlorhexidine Gluconate for Treatment of Oral

Lucia Liu, Bryn Launer, Evelyn Flores, Greg Tchakalian, Barry Kreiswirth, Michael Bolaris, Tae Kim, Kelly D Young, Loren G Miller

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lucia LiuDuke University School of Medicine, Durham, North Carolina, USA.ORCID https://orcid.org/0009-0004-5235-3382
Bryn LaunerVanderbilt University Medical Center, Nashville, Tennessee, USA.
Evelyn FloresLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, USA.
Greg TchakalianUniversity of Southern California School of Pharmacy, Los Angeles, California, USA.
Barry KreiswirthCenter for Discovery and Innovation, Hackensack, New Jersey, USA.
Michael BolarisLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, USA.
Tae KimLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, USA.
Kelly D YoungLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, USA.
Loren G MillerLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, USA.ORCID https://orcid.org/0000-0003-0487-1711

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Methods: We performed a prospective, double-blind, randomized controlled clinical trial of twice-daily 0.12% chlorhexidine gluconate (CHG) gargle vs a placebo for 7 days in healthy children oropharyngeally colonized with Results: We screened 189 children, 120 (63%) of whom had Conclusions: We found that a 7-day 0.12% chlorhexidine gluconate mouthwash regimen significantly reduced

Indexed as

chlorhexidine gluconatedecolonizationoropharyngeal colonizationrandomized clinical trialStaphylococcus aureus

Identifiers

PMID41846597
PMCPMC12989745

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.